Application of Artificial Intelligence and Machine Learning in Pharmaceutical Analysis: Prediction of Drug Stability, Quality, and Degradation Profiles

Abstract

ABSTRACT Pharmaceutical stability testing, critical quality attribute (CQA) monitoring, and chemical degradation profiling form the bedrock of regulatory compliance, drug safety, and formulation shelf-life determination. Traditional stability testing protocols governed by the International Council for Harmonisation (ICH Q1A-Q1E) require exhaustive real-time and accelerated multi-month experimental regimens, incurring substantial analytical costs, API consumption, and prolonged development timelines. The integration of Artificial Intelligence (AI) and Machine Learning (ML) into pharmaceutical analytical science has catalyzed a paradigm shift toward predictive chemistry and real-time release testing. This comprehensive review examines modern AI/ML architectures—including quantitative structure-property relationships (QSPR), graph neural networks (GNNs), random forest ensembles, extreme gradient boosting (XGBoost), and physics-informed neural networks (PINNs)—applied to the modeling of drug stability, degradation pathways, and quality parameters. We analyze predictive methodologies across hydrolytic, oxidative, photolytic, and thermal degradation kinetics, evaluating performance metrics and feature representations. Furthermore, the integration of Process Analytical Technology (PAT), spectroscopic data, and Explainable AI (XAI) frameworks (SHAP, LIME) is evaluated under Quality by Design (QbD) principles. Finally, translational bottlenecks, data scarcity challenges, and emerging regulatory roadmaps (FDA, EMA) governing algorithmic validation in pharmaceutical manufacturing are critically assessed.

KEYWORDS: Artificial Intelligence, Machine Learning, Pharmaceutical Analysis, Drug Stability Prediction, Degradation Kinetics, Physics-Informed Neural Networks, Quality by Design, In Silico Shelf-Life Modeling.